Billions more in profits are at stake for some vaccine makers as the US moves toward dispensing Covid-19 booster shots to shore up Americans’ protection against the virus.

How much the manufacturers stand to gain depends on how big the rollout proves to be.

The Covid-19 crisis is constantly evolving, and some top US health officials expect boosters will be more broadly authorised in the coming weeks or months. And that, plus continued growth in initial vaccinations, could mean a huge gain in sales and profits for Pfizer and Moderna in particular.

“The opportunity quite frankly is reflective of the billions of people around the world who would need a vaccination and a boost,” Jefferies analyst Michael Yee said.

Read the full AP story here.